In particular, the KRASG12D mutation and MEK/ERK pathway activation was shown to up-regulate production of IL-10 and TGF-β, thus promoting CD4 T cells conversion in Tregs in pancreatic cancer [60]. This evidence concerns the gene MAP2K7 and familial pancreatic carcinoma.